





Merger Between BDMS and Health Network Analyst Presentation

December 15, 2010













Important Notice

- The information contained in this presentation is for information purposes only and does not constitute an offer or invitation to sell or the solicitation of an offer or invitation to purchase or subscribe for share in Bangkok Dusit Medical Services Public Company Limited ("BGH" and shares in BGH, "shares") in any jurisdiction nor should it or any part of it from the basis of , or be relied upon in any connection with, any contract or commitment whatsoever.
- This presentation may include information which is forward-looking in nature. Forward-looking information involve known and unknown risks, uncertainties and other factors which may impact on the actual outcomes, including economic conditions in the markets in which BGH operates and general achievement of BGH business forecasts, which will cause the actual results, performance or achievements of BGH to differ, perhaps materially, from the results, performance or achievements expressed or implied in this presentation.
- This presentation has been prepared by the BGH. The information in this presentation has not been independently verified. No representation, warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information and opinions in this presentation. None of the BGH or any of its agents or advisors or any of their respective affiliates, advisors or representatives, shall have any liability (in negligence or otherwise) for any loss howsoever arising from any use of this presentation or its contents or otherwise arising in connection with this presentation.
- This presentation is made, furnished and distributed for information purposes only. No part of this presentation shall be relied upon directly or indirectly for any investment decision-making or for any other purposes.
- This presentation and all other information, materials or documents provided in connection therewith, shall not, either in whole or in part, be reproduced, redistributed or made available to any other person, save in strict compliance with all applicable laws.

















Introduction to Speakers



Mr. Wallop AdhikomprapaDirector / Executive Advisor
BDMS



Mrs. Narumol Noi-Am Chief Financial Officer BDMS



Ms. Ajaya Intaraprasong
Finance Director, Investor
Relations
BDMS



Mr. Itti Thongtang
Director
HNC
Chairman of Executive Committee
Paolo Group



Mr. Paiboon Fuengfuskul
Director / Chief Financial
Officer
HNC

















Table of Contents

	Page
Transaction Summary	6
Transaction Rationale	10
Transaction Overview	20
HNC Assets Overview	24
Valuation	27
Pro-Forma Financial Results	30
Timetable	34





















Transaction Summary














Structure and Shareholdings of HNC



















Transaction Summary

- Merging with Health Network Public Company Limited (HNC)
 - 1. 4 hospitals under Phyathai Brand
 - 2. 4 hospitals under Paolo Brand
- Transaction Value of no more than Bt 12,121 mm (Transaction Size of no more than Bt 12,551 mm) comprising of
 - 1. Entire Business Transfer (EBT) from HNC with total value of Bt 9,395 mm (Transaction Size of Bt 9,825 mm)
 - BGH to offer no more than 230,870,405 newly issued shares as consideration at Bt 37.75 per share or equivalent to **Bt 8,715 mm** and **Bt 680 mm as cash consideration** with total transaction value of Bt 9,395 mm
 - Accepting the transfer of **Bt 430 mm intercompany loan** from HNC (Does not impact valuation as the creditor of such loan is among the company to be transferred under EBT)
 - Private Placement to HNC major shareholders for no more than **4,127,864 shares** at Bt 37.75 per share or equivalent to **Bt 156 mm**
 - Net cash to be used in the transaction after PP is **Bt 524 mm**
 - Total number of newly issued shares is **234,998,269 shares**
 - 2. Tender Offer for shares held by minority shareholders of Prasit Patana Public Company Limited (PPCL) with total value of Bt 2,726 mm
 - If only <u>cash</u> is used as consideration, will require <u>Bt 2,726 mm</u>
 - If only **share** is used as consideration, will require **72,198,801 newly issued shares** at Bt 37.75 per share

















Transaction Summary (Cont'd)

- Impact to shareholders
 - Newly issued shares of **no more than 307,197,070 shares** for the whole transaction
 - Resulting in control dilution of <u>15.9% for the case where only cash</u> is used as consideration and <u>19.8%</u>
 <u>for the case where only share</u> is used for consideration for the Tender Offer
 - As valuation is conducted based on valuation multiples that are lower than BGH's trading multiples, the transaction will result in earnings accretion of <u>23.0% in case of cash only</u> and <u>19.2% in case of share only</u>





















Transaction Rationale














Transaction Rationale

Addition of Two New and Well Recognized Hospital **Brands to the Group and Diversification** of Patient Mix




















Enhanced
Market
Share and
Extensive
Coverage



















Entry into New Market Opportunities in Civil Servant Healthcare


Participation in Bangkok:

- Phyathai 2
- Phyathai 3
- Paolo Medic
- Paolo Chok Chai 4
- Paolo Nawamin

Other Provinces:


- Samitivej Sriracha
- Phyathai Sriracha
- Paolo Samut Prakarn

Estimated Healthcare Market Size



Source: SSO, NHSO, WHO, BOT, Phatra Securities Estimates

Participation in Civil Servant Healthcare




















PostTransaction,
BGH will
Become the
#1
Healthcare
Operator in
Thailand,
Together
With a
Leading
Position in
Asia



- (1) Includes BGH's hospitals in Cambodia namely Royal Rattanak International and Royal Angkor International
- (2) BGH's market capitalization based on share price of Bt 37.75 per share



















Financial Returns from the Merger





- (1) HNC's revenue, net income, EPS and total assets include PPCL, PYTS and PNwm
- (2) For hospitals that are listed on stock exchange

















Synergies
Creation from
Integration of
the New Group



Integration in areas of:

- Pooling of medicine, supplies, and equipment purchasing
- Central supporting functions such as ambulatory services, accounting, IT and laboratory functions
- Cross referrals
- Allow BGH to tap new patient demographic
- Entrance into Social Security scheme
- Opportunity to penetrate into Civil Servant Healthcare scheme

















Cooperation of
Highly
Experienced
Personnel
Including Skilled
Senior
Management,
Doctors,
Nurses, and
Other
Employees

PPCL Group



Mr. Wichai Thongtang Chairman of the Board



Mr. Att Thongtang Chief Executive Officer



Ambhanwong
Director /
Chief Medical
and
International
Business
Officer



Fuengfuskul
Director / CFO



Mr. Kraiwin Srikraiwin Director / COO



Mr. Thana Thiramanus Director / CMSO

Paolo Group



Thongtang
Director /
Chairman of
Executive
Committee



Mr. Sitthichai Sukchareonmitr Managing

Managing Director



Mr. Suthep Tansa-Nguanwong

Deputy Managing Director Operations and Support Division



Mr. Benja Asanapetch

Deputy Managing Director Business Development and Service



Dr. Pichai Praepath

Hospital Director, PMed

















Key Statistics







Post Transaction – Merge Co

			-	I .	
Operational Statistics(1)	BGH	Phyathai Group	Paolo Group	Total	Change (%)
Number of hospitals	19	4	4	27	42%
Number of registered beds	2,992	990	657	4,639	55%
Number of available beds	2,271	828	684	3,783	67%
OPD per day	10,226	5,484	4,472	20,182	97%
IPD per day	1,523	512	361	2,396	57%
OPD billing	2,890	1,914	1,585	1 1 1 1	
IPD billing / patient days	23,313	17,422	13,378	 	
IPD utilization	67%	61%	53%		
Financials Statistics (Bt mm)					
Revenue				 	
2009	21,974	6,917	3,177	32,068	46%
9M10	17,857	5,267	2,418	25,542	43%
EBITDA				 	
2009	5,048	1,378	708	7,134	41%
9M10	4,341	1,336	602	6,279	45%
Net Income				 	
2009	1,725	361	290	2,356	37%
9M10	1,803	537	330	2,670	48%
Valuation	47,040	8,690	5,123	58,637	25%
				•	

Source: Company Financial Statements and Management Accounts

Notes: Operating data for BGH is based on 9M10 management account. Operating data for HNC is based on 1H10 management account and is inclusive of PYTS and PNwm Financial data is based on company financial statements except for financial data of Paolo Group for 9M10 which is based on management account Financial data for Phyathai Group is inclusive of PYTS. Financial data for Paolo Group is inclusive of PNwm




















Hospital Regional Rankings









Source: Bloomberg as of December 1, 2010, 9M10 Company Financial Statements for BGH and HNC, and 9M10 Management Account for PNwm Note: Exchange rate of Bt 30.1 / US\$ 1

- (1) Financial data for HNC and Merge Co include PPCL, PYTS and PNwm
- (2) BGH's market capitalization is based on share price of Bt 37.75 per share





















Transaction Overview















Transaction Structure



Entire Business Transfer (EBT)

- 1 BGH will purchase all of HNC's assets (PPCL and Paolo shares) using newly issued shares and cash as consideration with a total value of Bt 9,395 mm
 - Cash Bt 680 mm
 - Shares 230,870,405
 - Novation of intercompany loan and accrued interests with a total value of Bt 430 mm to BGH
- 2 HNC will pay dividend to its shareholders and register for dissolution and liquidate. BGH's shares received from EBT transaction will be allocated to HNC's shareholders



Private Placement

3 BGH will issue new shares through a private placement of 4,127,864 shares with a total value of Bt 156 mm to HNC's major shareholders


















Transaction Structure (Cont'd)



Mandatory Tender Offer of PPCL

- BGH will cross 50% holding after acquiring PPCL's shares from HNC and trigger mandatory tender offer for all of the remaining shares in PPCL at the same price BGH bought from HNC
- 4 BGH will issue new shares or use cash as consideration for the mandatory TO. The maximum amount of shares for the mandatory TO will be 72,198,801 shares or total cash of Bt 2,726 mm (PPCL at Bt 3.71 per share)

BGH S/H HNC S/H Minority of PPCL BGH ~ 100% PPCL Paolo

Post Merger Structure

- Total Transaction value of Bt <u>12,121 mm</u> with a consideration of:
 - 307,197,070 newly issued shares and total cash of <u>Bt</u>
 524 mm in case tender offer to minority shareholders of PPCL is made <u>with shares</u>
 - 234,998,269 newly issued shares and total cash of <u>Bt</u>
 3,250 mm in case tender offer to minority shareholders of PPCL is made <u>with cash</u>


















Post-Transaction Shareholding Structure



Post-Transaction BGH's Shareholding

	Pre-Tra	ansaction	Post-Transaction			
			T/O with Cash		T/O with Shares	
Shareholding	# of Shares (mm)	% Holding	# of Shares (mm)	% Holding	# of Shares (mm)	% Holding
BGH	1,246	100.0%	1,246	84.1%	1,246	80.2%
HNC	-	-	235	15.9%	235	15.1%
Minority of PPCL	-	-	-	-	72	4.6%
Total	1,246	100.0%	1,481	100.0%	1,553	100.0%





















HNC Assets Overview

















Financial Performance: PPCL Group









Source: Financial statements of the company

(1) Capital structure does not include PYTS except for the 9M ended September 30, 2010 where PPCL holds more than 50% of PYTS





















Financial Performance: Paolo Group









Source: Company Financial statements and Management Account of Paolo group for 9M ended September 30, 2010

Note: Calculation of financial data of Paolo Group for 2004-2006 is based on the sum of financial data of each hospital in the group whereas financials of Paolo Group from 2007 onwards are based on HNC's consolidated financial statements. Financial figures of Paolo Group does not include PNwm except for in 9M10 where HNC holds more than 50% in PNwm. Figures for PNwm are exclusive of extraordinary items.





















Valuation














HNC Valuation (Excluding intercompany loan of Bt 430 mm novated to BGH)



Financial figures are effective figures based on HNC's holding in each company. Financials of HNC, PPCL and Paolo based on the sum of financials of each hospital in the Group. LTM revenue and LTM EBITDA are exclusive of interest income Excluding BGH's holding in PPCL of 19.5%;

Blended effective shareholding of HNC in PMed, PSamut, PChok, and PNwm


















Comparison of HNC Valuation with Various Valuation Multiples

Equity Value (Bt mm) BGH 47,040 (1) HNC 9,395 BH 28,407 KH 10,640

Equity value of BGH is based on Bt 37.75 per share







Source: Financial statements for BGH, Management account for HNC and Bloomberg data for BH and KH
(1) Based on calculation of Bt 37.75 per share for total number of shares of 1,246,094,337 shares (fully diluted shares of BGH).





















Pro-Forma Financial Results















Pro-Forma Financial Results





Note: Financial figures for HNC includes PPCL, PYTS and PNwm.


















Pro-Forma Financial Results (Cont'd)



Source: Company financial statements

Note: Financial figures for HNC includes PPCL, PYTS and PNwm.

(1) Assume BGH incur debt of Bt 1,500 mm with interest rate of 5% to finance the cash component of the transaction.

















Pro-Forma Financial Results (Cont'd)

	LTM (Shares for Tender Offer of PPCL)		LTM (Cash for Tender Offer of PPCL) (1)		
	Pre-Transaction	Post-Transaction	Pre-Transaction	Post-Transaction	
Debt / Equity (3Q10)	0.7x	0.6x	0.7x	0.7x	
Debt / EBITDA (LTM)	1.9x	2.1x	1.9x	2.2x	
BITDA / Interest (LTM	9.1x	8.9x	9.1x	8.2x	
Bt mm		913		988	
Expense (LTM)	614	299	614	374	
Exp (C	614	614	614	614	
Bt mm		16,809		18,309	
Debt (3Q10)	10,844	5,965	10,844	7,465	
Deb	10,844	10,844	10,844	10,844	
Bt mm					
Q10		27,219		24,441	
Equity (3Q10)	15,622	11,597	15,622	8,819	
Equ	15,622	15,622	15,622	15,622	

Source: Company financial statements

Note: Financial figures for HNC includes PPCL, PYTS and PNwm.

Assume BGH incur debt of Bt 1,500 mm with interest rate of 5% to finance the cash component of the transaction.





















Timetable














Timetable



















For more information & updates :- www.bangkokhospital.com















